fda clear zbh rosa knee systema expect
chang view
morn zimmer biomet announc fda grant clearanc zimmer biomet rosa knee system robotically-
assist total knee replac surgeri news expect manag indic expect approv come
origin expect around end earlier month investor present
clearanc chang view zimmer biomet zbh-rate underweight chang view syk-rat
overweight expect traction rosa take time believ plenti room continu grow mako franchis
expect zimmer biomet discuss product detail upcom earn call februari highlight system
upcom american academi orthoped surgeon aao meet march report next tuesday januari smith
nephew report result februari
fda grant clearanc zimmer biomet rosa knee system robotically-assist surgeri
clearanc anticip time in-lin ith manag commentari earlier month approv
rosa system provid continuum data analysi assist surgeon use comput softw technolog control
move surgic instrument ith goal greater precis flexibl procedur rosa knee featur x-atla
imag protocol x-ray base preoper imag creat model plan patient bone anatomi ell
intraop real-tim map patient anatomi motion
rosa knee system leverag zimmer biomet rosa robot platform hich includ rosa brain neurosurg
procedur zimmer biomet also expect approv rosa spine
zimmer biomet rosa knee system ill compet market lead orthoped robotic-assist system stryker mako
system smith nephew also offer navio system aid physician knee replac surgeri develop
system ell hich acquir orthotaxi hich slate market launch
conjunct ith initi sector conduct survey orthoped surgeon pleas see report
medic suppli devic posit fundament continu initi ith posit view section review ing result begin
page survey conclud like remain leader robot took mako subsequ
follow ing acquisit year drive adopt market believ ill take hile zimmer biomet see
notabl benefit financi perspect
kristen stew art cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
master limit partnership mlp pass-through entiti structur publicli list partnership tax purpos
distribut unit holder may treat return princip investor consult ow tax advisor
invest unit
valuat methodolog set price target primarili reli forw ard price-to-earnings methodolog price target
 hich appli pe multipl ep estim
risk may imped achiev barclay research valuat price fx rate recent acquisit
could pressur earn grow th competit pressur particularli area knee competitor launch compet
robotic-assist system could impact grow th outlook sentiment tow ard stock time ultim receipt new
product approv could affect outlook risk includ signific chang reimburs potenti dilut associ
 ith acquisit product failur fda govern action
rate price target histori
prior intra-day chang may publish rate secur underw eight
adjust price target
histor stock price price target may adjust stock split dividend
valuat methodolog set price target primarili reli forw ard price-to-earnings methodolog price target
appli multipl ep estim
risk may imped achiev barclay research valuat price upsid resolut fda
matter acceler top line grow th nside delay new product approv failur see signific increas new
includ signific reimburs chang competit pressur dilut associ ith potenti acquisit integr
acquir busi proce sale busi fda govern action
rate price target histori
prior intra-day chang may publish rate secur overw eight
adjust price target
histor stock price price target may adjust stock split dividend
price sourc refinitiv last avail close price relev trade market unless anoth time sourc
indic
